Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
113 hedge funds and large institutions have $219M invested in Mersana Therapeutics in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 17 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 32
0.05% more ownership
Funds ownership: 3.73% → 3.78% (+0.05%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $230M → $219M (-$10.1M)
6% less funds holding
Funds holding: 120 → 113 (-7)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
37% less call options, than puts
Call options by funds: $770K | Put options by funds: $1.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$4.48M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$3.21M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.94M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$2.28M |
| 5 |
EAM
Exome Asset Management
New York
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.23M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.82M |
| 3 |
Renaissance Technologies
New York
|
-$1.69M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.61M |
| 5 |
Morgan Stanley
New York
|
-$1.6M |
MRSN Hedge Fund Activity: Q3 2024 in Review
113 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q3 2024, worth a combined $219M — down 4.4% from $230M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of MRSN and 11 opened new positions — a net loss of 6 holders — while 32 trimmed existing stakes and 39 added.
The largest buyer was Nextech Invest, adding an estimated $4.48M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $5.23M sold.
- 113 institutional investors held Mersana Therapeutics (MRSN) as of Q3 2024, down from 120 in Q2 2024.
- Funds reported $219M of Mersana Therapeutics stock for Q3 2024, down 4.4% quarter-over-quarter.
- 11 funds opened new Mersana Therapeutics positions in Q3 2024 and 17 closed out, a net change of -6 holders.
- The largest Mersana Therapeutics buyer in Q3 2024 was Nextech Invest, an estimated $4.48M added.
- The largest Mersana Therapeutics seller in Q3 2024 was Cormorant Asset Management, an estimated $5.23M sold.
Based on aggregated 13F filings for Q3 2024.